# A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

> **NCT01516918** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 103 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** VX-222
- **DRUG:** telaprevir
- **DRUG:** ribavirin
- **BIOLOGICAL:** peginterferon-alfa-2a

## Key facts

- **NCT ID:** NCT01516918
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-09
- **Final completion:** 2013-12
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516918, "A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01516918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*